SIM0709
Boehringer Ingelheim Signs $1.3 Billion Deal for Simcere’s Preclinical IBD Bispecific SIM0709
Boehringer Ingelheim; Simcere; SIM0709; IBD; bispecific antibody; TL1A; IL-23p19; licensing deal
Actionable Insights Powered by AI
Boehringer Ingelheim; Simcere; SIM0709; IBD; bispecific antibody; TL1A; IL-23p19; licensing deal